S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

AstraZeneca (AZN) Stock Forecast, Price & News

+1.67 (+2.59%)
(As of 05/20/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
7.17 million shs
Average Volume
7.54 million shs
Market Capitalization
$205.17 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

AstraZeneca logo

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical Preparation Manufacturing
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Outstanding Shares
Free Float
Market Cap
$205.17 billion

Company Calendar

Last Earnings


Overall MarketRank

0.83 out of 5 stars

Manufacturing Sector

6th out of 20 stocks

Pharmaceutical Preparation Manufacturing Industry

2nd out of 4 stocks

Analyst Opinion: 0.0Community Rank: 3.3Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

AstraZeneca (NYSE:AZN) Frequently Asked Questions

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NYSE:AZN) released its quarterly earnings data on Friday, April, 29th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.86 by $0.09. The business had revenue of $11.39 billion for the quarter, compared to the consensus estimate of $11.19 billion.
View AstraZeneca's earnings history

Is AstraZeneca a good dividend stock?

AstraZeneca pays an annual dividend of $1.93 per share and currently has a dividend yield of 2.99%.

Who are AstraZeneca's key executives?
AstraZeneca's management team includes the following people:
  • Mr. Pascal Soriot D.V.M., M.B.A., CEO & Exec. Director (Age 63, Pay $5.82M)
  • Dr. Aradhana Sarin M.D., CFO & Exec. Director (Age 47, Pay $4.3M)
  • Mr. Marc Dunoyer, CEO of Alexion & Chief Strategy Officer (Age 70, Pay $2.04M)
  • Ms. Pam P. Cheng, EVP of Operations & Information Technology and Member of External Sustainability Advisory Board (Age 51)
  • Mr. Chris Sheldon, Head of Investor Relations
  • Mr. Jeffrey Pott, EVP of HR, Chief HR Officer, Gen. Counsel & Member of External Sustainability Advisory Board
  • Ms. Katarina Ageborg, EVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory Board
  • Gonzalo Vina, Head of Global Media Relations
  • Dr. Menelas Pangalos Ph.D., EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory Board (Age 55)
  • Dr. Ruud Dobber Ph.D., Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Moderna (MRNA), Tesla (TSLA), AbbVie (ABBV), AT&T (T), Advanced Micro Devices (AMD) and Walmart (WMT).

What is AstraZeneca's stock symbol?

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately $66.21.

How much money does AstraZeneca make?

AstraZeneca has a market capitalization of $205.17 billion.

How many employees does AstraZeneca have?

AstraZeneca employs 83,100 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue, Cambridge, Cambridgeshire CB2 0AA. The company can be reached via phone at 442037495000.

This page was last updated on 5/21/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.